Quadrant Capital Group’s Gyre Therapeutics GYRE Stock Holding History

Quadrant Capital Group’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-45	Closed	-$1K	–	2553
2021 Q2	$1K	Buy	+45	New	+$1.54K	﹤0.01%	2272

Other funds holding GYRE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Quadrant Capital Group's GYRE Position: Q3 2021 in Review

Quadrant Capital Group sold out of Gyre Therapeutics (GYRE) in Q3 2021, closing a stake of 45 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in GYRE in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 65 funds tracked by Wall St. Rank hold GYRE as of Q3 2021.

Quadrant Capital Group reported no remaining Gyre Therapeutics position as of Q3 2021 after selling out during the quarter.
Quadrant Capital Group sold 45 Gyre Therapeutics shares in Q3 2021, an estimated $1K.
Quadrant Capital Group first reported a position in Gyre Therapeutics in Q2 2021 and held it in 1 quarter.
Quadrant Capital Group's Gyre Therapeutics position peaked at $1K in Q2 2021.
65 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2021.

Based on Quadrant Capital Group's 13F filing for Q3 2021, filed 12 Nov 2021.